BCM
QNCX icon

Bridgeway Capital Management’s Quince Therapeutics QNCX Stock Holding History

Bridgeway Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-476
Closed -$319K – 1302
2025
Q4 		$319K Hold
476
– – 0.01% 920
2025
Q3 		$155K Sell
476
-167
-26% -$55.6K ﹤0.01% 1052
2025
Q2 		$212K Buy
643
+111
+21% +$25.4K 0.01% 951
2025
Q1 		$142K Buy
532
+70
+15% +$21.4K ﹤0.01% 988
2024
Q4 		$173K Buy
462
+20
+5% +$6.01K ﹤0.01% 1034
2024
Q3 		$68.7K Sell
442
-250
-36% -$35.8K ﹤0.01% 1193
2024
Q2 		$104K Hold
692
– – ﹤0.01% 1161
2024
Q1 		$147K Hold
692
– – ﹤0.01% 1158
2023
Q4 		$145K Hold
692
– – ﹤0.01% 1191
2023
Q3 		$155K Buy
692
+417
+152% +$109K ﹤0.01% 1142
2023
Q2 		$82.8K Sell
275
-275
-50% -$85.6K ﹤0.01% 1282
2023
Q1 		$172K Hold
550
– – ﹤0.01% 1130
2022
Q4 		$70.1K Hold
550
– – ﹤0.01% 1259
2022
Q3 		$146K Buy
+550
New +$209K ﹤0.01% 1205

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bridgeway Capital Management's QNCX Position: Q1 2026 in Review

Bridgeway Capital Management sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 476 shares — an estimated $319K sold.

Bridgeway Capital Management first reported a position in QNCX in Q3 2022 and held it in 14 quarters. The position peaked at $319K in Q4 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Bridgeway Capital Management reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 476 Quince Therapeutics shares in Q1 2026, an estimated $319K.
  • Bridgeway Capital Management first reported a position in Quince Therapeutics in Q3 2022 and held it in 14 quarters.
  • Bridgeway Capital Management's Quince Therapeutics position peaked at $319K in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.